NASDAQ · PBM

Psyence Biomedical news

$5.42−4.41%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About Psyence Biomedical

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

GlobeNewswire Inc.Feb 13, 6:30 PM ET▲ Positive

The company secured a strategic manufacturing partnership with a leading psychedelic producer, gaining access to reliable pharmaceutical-grade supply while preserving financial flexibility through a put option structure rather than upfront capital deployment. This de-risks the clinical development pathway and supports future commercialization efforts.

Also mentions PBM

Articles that tag PBM but are mainly about other companies.

None recently.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology